my mistake, the drug is called custirsen....not clusterin....either way, not a grabber. How about clusterin buster? Protein beater?
The report by McCamant, the editor, notes a competitive advantage of custirsen lies in its pain relief. In a competitive landscape, this desirable feature distinguishes the drug.
Here are my thoughts, the survival benefits, low costs and compatibility with other drugs in the landscape, plus its pain advantage, makes 011 or custirsen a mighty attractive drug candidate for the FDA.